MeiraGTx Holdings (MGTX) is back in focus after securing a financing agreement with Oberland Capital that could provide up to $400 million, including a large non dilutive royalty component tied to future product revenues.

At a latest share price of $13.94, MeiraGTx Holdings has seen a strong 30 day share price return of 51.36% and a 90 day share price return of 55.41%. The year to date share price return of 78.49% and 3 year total shareholder return of 110.57% point to momentum that recent financing news with Oberland Capital appears to have reinforced, even as the 1 year total shareholder return of 61.72% contrasts with a near flat 5 year total shareholder return of 0.71%.

If you are weighing what this kind of financing means for other growth stories in healthcare, it is a good moment to see what is happening across 40 healthcare AI stocks

MeiraGTx Holdings now has fresh capital, a complex mix of royalties and equity, and a share price that has already reacted. The next step is simple: is the stock’s current valuation in line with that setup or not?

Price-to-Sales of 16.2x: Is It Justified for MeiraGTx Holdings?

On a simple yardstick, MeiraGTx Holdings trades on a P/S of 16.2x, which sets expectations high relative to the current share price of $13.94.

The P/S ratio compares the company’s market value with its revenue and is often used for businesses that are still loss making, like MeiraGTx Holdings. At 16.2x, investors are effectively paying a significant premium for each dollar of the company’s $79.758 million in reported revenue, which implies the market is comfortable focusing on sales traction rather than present profitability.

Against the broader US Biotechs industry average P/S of 12.4x, MeiraGTx Holdings trades at a higher level, which suggests the stock is priced more optimistically than the sector overall. However, when lined up against a peer average P/S of 18.6x and an estimated fair P/S ratio of 17.8x, its 16.2x multiple sits slightly below both. This hints at room for the market to shift closer to those reference points if forecasts play out as expected.

Result: Price-to-Sales of 16.2x (ABOUT RIGHT)

However, MeiraGTx Holdings still faces key risks, including ongoing net losses of $120.533 million and the execution uncertainty that comes with a broad, early stage pipeline.

Next Steps

With MeiraGTx Holdings showing both fresh funding momentum and clear execution questions, it is worth checking the underlying data yourself and deciding quickly where you stand. To see in one place both the potential upsides and the key concerns investors are watching, review the 1 key reward and 3 important warning signs

Looking for more investment ideas beyond MeiraGTx Holdings?

If MeiraGTx Holdings has your attention, do not stop there. Use clear filters to spot other stocks that might fit your goals before the crowd catches on.

• Target reliable income by checking out 9 dividend fortresses that already offer higher yields.
• Hunt for potential bargains using the 44 high quality undervalued stocks that combine quality fundamentals with attractive pricing.
• Zero in on financial strength with the solid balance sheet and fundamentals stocks screener (47 results) so you focus on companies built to handle tougher conditions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.